Data on cholesterol drug fenofibrate lead to FDA advisory

11/9/2011 | Medscape (free registration)

Data from the ACCORD Lipid trial showed the cholesterol-lowering drug fenofibric acid or fenofibrate may not reduce the risk of major cardiovascular events, leading the FDA to issue a safety communication and update prescribing information. The agency also asked for a trial to study the medication's cardiovascular effects in patients on statins.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ